Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Quantitative Assessment the Relationship between p21 rs1059234 Polymorphism and Cancer Risk

  • Huang, Yong-Sheng (Institute of Basic Medical Sciences and School of Basic Medicine, Peking Union Medical College and Chinese Academy of Medical Sciences) ;
  • Fan, Qian-Qian (Institute of Basic Medical Sciences and School of Basic Medicine, Peking Union Medical College and Chinese Academy of Medical Sciences) ;
  • Li, Chuang (Institute of Basic Medical Sciences and School of Basic Medicine, Peking Union Medical College and Chinese Academy of Medical Sciences) ;
  • Nie, Meng (Institute of Basic Medical Sciences and School of Basic Medicine, Peking Union Medical College and Chinese Academy of Medical Sciences) ;
  • Quan, Hong-Yang (Institute of Basic Medical Sciences and School of Basic Medicine, Peking Union Medical College and Chinese Academy of Medical Sciences) ;
  • Wang, Lin (Institute of Basic Medical Sciences and School of Basic Medicine, Peking Union Medical College and Chinese Academy of Medical Sciences)
  • Published : 2015.06.03
Download PDF
⟨ Previous Next ⟩

Abstract

p21 is a cyclin-dependent kinase inhibitor, which can arrest cell proliferation and serve as a tumor suppressor. Though many studies were published to assess the relationship between p21 rs1059234 polymorphism and various cancer risks, there was no definite conclusion on this association. To derive a more precise quantitative assessment of the relationship, a large scale meta-analysis of 5,963 cases and 8,405 controls from 16 eligible published case-control studies was performed. Our analysis suggested that rs1059234 was not associated with the integral cancer risk for both dominant model [(T/T+C/T) vs C/C, OR=1.00, 95% CI: 0.84-1.18] and recessive model [T/T vs (C/C+C/T), OR=1.03, 95% CI: 0.93-1.15)]. However, further stratified analysis showed rs1059234 was greatly associated with the risk of squamous cell carcinoma of head and neck (SCCHN). Thus, larger scale primary studies are still required to further evaluate the interaction of p21 rs1059234 polymorphism and cancer risk in specific cancer subtypes.

Keywords

References

  1. Carvalho IN, Reis AH, Cabello PH, et al (2013). Polymorphisms of CDKN1A gene and risk of retinoblastoma. Carcinogenesis, 34, 2774-7. https://doi.org/10.1093/carcin/bgt308
  2. Derynck R, Akhurst RJ, Balmain A (2001). TGF-beta signaling in tumor suppression and cancer progression. Nat Genet, 29, 117-29. https://doi.org/10.1038/ng1001-117
  3. Driver KE, Song H, Lesueur F, et al (2008). Association of single-nucleotide polymorphisms in the cell cycle genes with breast cancer in the British population. Carcinogenesis, 29, 333-41. https://doi.org/10.1093/carcin/bgm284
  4. Englert C, Maheswaran S, Garvin AJ, et al (1997). Induction of p21 by the Wilms’ tumor suppressor gene WT1. Cancer Res, 57, 1429-34.
  5. Gartel AL (2005). The conflicting roles of the cdk inhibitor p21(CIP1/WAF1) in apoptosis. Leuk Res, 29, 1237-8. https://doi.org/10.1016/j.leukres.2005.04.023
  6. Gartel AL, Tyner AL (2002). The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther, 1, 639-49.
  7. Guo W, Cui YJ, Fang SM, et al (2006). [Association of polymorphisms of p21cip1 and p27kip1 genes with susceptibilities of esophageal squamous cell carcinoma and gastric cardiac adenocarcinoma]. Ai Zheng, 25, 194-9.
  8. Jiang M, Shao ZM, Wu J, et al (1997). p21/waf1/cip1 and mdm-2 expression in breast carcinoma patients as related to prognosis. Int J Cancer, 74, 529-34. https://doi.org/10.1002/(SICI)1097-0215(19971021)74:5<529::AID-IJC9>3.0.CO;2-5
  9. Lei D, Sturgis EM, Liu Z, et al (2010). Genetic polymorphisms of p21 and risk of second primary malignancy in patients with index squamous cell carcinoma of the head and neck. Carcinogenesis, 31, 222-7. https://doi.org/10.1093/carcin/bgp279
  10. Li G, Liu Z, Sturgis EM, et al (2005). Genetic polymorphisms of p21 are associated with risk of squamous cell carcinoma of the head and neck. Carcinogenesis, 26, 1596-602. https://doi.org/10.1093/carcin/bgi105
  11. Li R, Waga S, Hannon GJ, et al (1994). Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature, 371, 534-7. https://doi.org/10.1038/371534a0
  12. Liu B, Zhang Y, Jin M, et al (2010). Association of selected polymorphisms of CCND1, p21, and caspase8 with colorectal cancer risk. Mol Carcinog, 49, 75-84.
  13. Liu F, Wei YG, Luo LM, et al (2013). Genetic variants of p21 and p27 and hepatocellular cancer risk in a Chinese Han population: a case-control study. Int J Cancer, 132, 2056-64. https://doi.org/10.1002/ijc.27885
  14. Liu S, Bishop WR, Liu M (2003). Differential effects of cell cycle regulatory protein p21(WAF1/Cip1) on apoptosis and sensitivity to cancer chemotherapy. Drug Resist Updat, 6, 183-95. https://doi.org/10.1016/S1368-7646(03)00044-X
  15. Ma H, Jin G, Hu Z, et al (2006). Variant genotypes of CDKN1A and CDKN1B are associated with an increased risk of breast cancer in Chinese women. Int J Cancer, 119, 2173-8. https://doi.org/10.1002/ijc.22094
  16. Polakova V, Pardini B, Naccarati A, et al (2009). Genotype and haplotype analysis of cell cycle genes in sporadic colorectal cancer in the Czech Republic. Hum Mutat, 30, 661-8. https://doi.org/10.1002/humu.20931
  17. Roninson IB (2002). Oncogenic functions of tumour suppressor p21(Waf1/Cip1/Sdi1): association with cell senescence and tumour-promoting activities of stromal fibroblasts. Cancer Lett, 179, 1-14. https://doi.org/10.1016/S0304-3835(01)00847-3
  18. Shao A, Zheng L, Chen S, et al (2014). p21, p53, TP53BP1 and p73 polymorphisms and the risk of gastric cardia adenocarcinoma in a Chinese population. Biomarkers, 1-7.
  19. Sherr CJ (1996). Cancer cell cycles. Science, 274, 1672-7. https://doi.org/10.1126/science.274.5293.1672
  20. Sivonova MK, Vilckova M, Jurecekova J, et al (2013). The role of p21 3'UTR gene polymorphism in the risk of prostate cancer: a pilot study. Mol Med Rep, 7, 986-90. https://doi.org/10.3892/mmr.2012.1242
  21. Suzuki H, Ito R, Ikeda K, et al (2012). TATA-binding protein (TBP)-like protein is required for p53-dependent transcriptional activation of upstream promoter of p21Waf1/Cip1 gene. J Biol Chem, 287, 19792-803. https://doi.org/10.1074/jbc.M112.369629
  22. Taghavi N, Biramijamal F, Abbaszadegan MR, et al (2010). P21(waf1/cip1) gene polymorphisms and possible interaction with cigarette smoking in esophageal squamous cell carcinoma in northeastern Iran: a preliminary study. Arch Iran Med, 13, 235-42.
  23. Waga S, Li R, Stillman B (1997). p53-induced p21 controls DNA replication. Leukemia, 11, 321-3.
  24. Wakasugi E, Kobayashi T, Tamaki Y, et al (1997). p21(Waf1/Cip1) and p53 protein expression in breast cancer. Am J Clin Pathol, 107, 684-91. https://doi.org/10.1093/ajcp/107.6.684
  25. Wang N, Wang S, Zhang Q, et al (2012). Association of p21 SNPs and risk of cervical cancer among Chinese women. BMC Cancer, 12, 589. https://doi.org/10.1186/1471-2407-12-589
  26. Wu X, Gu J, Grossman HB, et al (2006). Bladder cancer predisposition: a multigenic approach to DNA-repair and cell-cycle-control genes. Am J Hum Genet, 78, 464-79. https://doi.org/10.1086/500848
  27. Xiong Y, Hannon GJ, Zhang H, et al (1993). p21 is a universal inhibitor of cyclin kinases. Nature, 366, 701-4. https://doi.org/10.1038/366701a0
  28. Yin D, Jiang Y, Zhang S, et al (2015). No association between p21 Gene rs1059234 polymorphisms and risk of endometrial cancer among han women in northeast China. Cell Biochem Biophys, 71, 167-71. https://doi.org/10.1007/s12013-014-0180-5
  29. Zheng L, Tang W, Shi Y, et al (2014). p21 rs3176352 G>C and p73 rs1801173 C>T polymorphisms are associated with an increased risk of esophageal cancer in a Chinese population. PLoS One, 9, 96958. https://doi.org/10.1371/journal.pone.0096958

Cited by

  1. The effects of p21 gene C98A polymorphism on development of uterine leiomyoma in southeast Iranian women vol.37, pp.9, 2016, https://doi.org/10.1007/s13277-016-5078-y